Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants
Authors' conclusion
Based on the PK and safety evaluations, ecnoglutide does not cause clinically significant PK interactions with rosuvastatin or digoxin.
Study context
- Population
- Healthy adultsreceived ≥1 dose
- Participants
- 28 adults
- Comparison
- Rosuvastatin and digoxin with steady-state ecnoglutide vs alone
- Outcome
- PK parameters of rosuvastatin and digoxin
Methodological detailsPhase 1 crossover, open-label, single-sequence crossover
- Phase 1 crossover
- Open-label
- Single-sequence crossover
Main finding
As reported in the abstract
AUC from time zero to infinity
Geometric mean (GM) ratio (rosuvastatin)
106%
90% CI 94%–120%
With ecnoglutide
GM ratio (digoxin)
84%
90% CI 76%–94%
With ecnoglutide
Further findings
Digoxin Cmax
Digoxin Cmax
- Remained within the therapeutic window
Body weight · 14-week intervention
- Mean decrease in body weight with ecnoglutide
- 11.2%
Safety
- Serious adverse events (AEs)
- 0
- Most common AEs were weight loss and gastrointestinal AEs
Original publication
Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes Obes Metab. Published 17 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →